February 11, 2008 – Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, announced completion of treatment in an 80 patient multi-center open label, randomized, parallel group Phase II study in India to determine the safety and efficacy of add-on intranasal insulin spray (Nasulin®) in patients with type 2 diabetes mellitus on oral anti-diabetic therapy. The clinical study report is expected to be completed later this month, but preliminary clinical results are being released today... [PDF] Bentley Pharmaceuticals' Press Release-
Wednesday, February 27, 2008
Bentley Pharmaceuticals, Phase II India clinical study in Type 2 diabetes
February 11, 2008 – Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, announced completion of treatment in an 80 patient multi-center open label, randomized, parallel group Phase II study in India to determine the safety and efficacy of add-on intranasal insulin spray (Nasulin®) in patients with type 2 diabetes mellitus on oral anti-diabetic therapy. The clinical study report is expected to be completed later this month, but preliminary clinical results are being released today... [PDF] Bentley Pharmaceuticals' Press Release-
